Cytokinetics announces initiation of phase 1 clinical study of AMG 594
Cytokinetics announced the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled, single/multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 594 in healthy subjects. AMG 594 is a cardiac troponin activator. February 20, 2019